- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07612839
Intravenous Lidocaine for Postoperative Fatigue After Laparoscopic TAPP Inguinal Hernia Repair (LIDO-TAPP)
The Effect of Intravenous Lidocaine on Postoperative Fatigue Syndrome in Patients Undergoing Elective Laparoscopic TAPP Inguinal Hernia Repair
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Postoperative fatigue may negatively affect recovery after surgery. Intravenous lidocaine has analgesic, anti-inflammatory, and opioid-sparing properties that may influence postoperative recovery.
This prospective randomized placebo-controlled trial will include adult patients undergoing elective laparoscopic transabdominal preperitoneal (TAPP) inguinal hernia repair under general anesthesia. Eligible participants will be randomly allocated to receive either perioperative intravenous lidocaine or an equal-volume 0.9% sodium chloride placebo according to the same administration schedule. Participants, anesthesia care providers, and postoperative outcome assessors will be blinded to treatment allocation.
The primary outcome is postoperative physical fatigue assessed using the Physical Fatigue subscale of the Multidimensional Fatigue Inventory-20 (MFI-20), with a preoperative baseline assessment and postoperative assessments on days 1, 3, 5, and 7. Secondary outcomes include postoperative pain intensity, cumulative tramadol consumption during the first 24 postoperative hours, postoperative nausea and vomiting, and the requirement for additional analgesia during the first 24 postoperative hours.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Hakan Emirkadı, MD
- Numéro de téléphone: +905322609367
- E-mail: hemirkadi@gmail.com
Lieux d'étude
-
-
Istanbul
-
Istanbul, Istanbul, Turquie (Türkiye), 34668
- University of Health Sciences Sultan Abdulhamid Han Training and Research Hospital
-
Contact:
- Hakan Emirkadı, MD
- Numéro de téléphone: +905322609367
- E-mail: hemirkadi@gmail.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Age 18 to 65 years
- Scheduled for elective laparoscopic transabdominal preperitoneal (TAPP) inguinal hernia repair
- American Society of Anesthesiologists (ASA) physical status I or II
- Able to understand and complete the Multidimensional Fatigue Inventory-20 (MFI-20)
- Written informed consent provided
Exclusion Criteria:
- Known allergy or hypersensitivity to lidocaine or other amide-type local anesthetics
- Clinically significant hepatic or renal dysfunction
- Clinically significant cardiac rhythm or conduction disorder
- Chronic opioid use
- Regular use of antiarrhythmic medication
- Pregnancy or breastfeeding
- Planned use of an additional local anesthetic technique during the study intervention
- Inability to complete the study assessments
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Lidocaine Group
Participants in this group will receive intravenous lidocaine based on ideal body weight.
A loading dose of 1.5 mg/kg will be administered intravenously over 10 minutes before surgery, followed by a continuous infusion of 1.5 mg/kg/hour until the end of surgery.
The infusion will be discontinued if signs suggestive of local anesthetic systemic toxicity or clinically significant unexplained hemodynamic or cardiac conduction abnormalities occur.
|
Perioperative intravenous lidocaine infusion will be administered according to the study protocol in patients undergoing elective laparoscopic TAPP inguinal hernia repair.
|
|
Comparateur placebo: Control Group
Participants in this group will receive an equal-volume 0.9% sodium chloride placebo administered according to the same timing and infusion protocol as the lidocaine group.
Standard perioperative care will otherwise be identical between groups.
|
0.9% sodium chloride will be administered intravenously as placebo in an equal volume and according to the same timing and infusion protocol as the lidocaine intervention.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
MFI-20 Physical Fatigue Subscale Score
Délai: Preoperative baseline and postoperative days 1, 3, 5, and 7
|
Postoperative physical fatigue will be assessed using the Physical Fatigue subscale of the Multidimensional Fatigue Inventory-20 (MFI-20).
The Physical Fatigue subscale consists of four items and ranges from 4 to 20 points, with higher scores indicating greater physical fatigue.
A preoperative assessment will be obtained as the baseline value.
Postoperative assessments will be performed on postoperative days 1, 3, 5, and 7.
|
Preoperative baseline and postoperative days 1, 3, 5, and 7
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Postoperative Pain Intensity (11-point Numeric Rating Scale)
Délai: 2, 4, 6, 12, and 24 hours after surgery and postoperative days 3, 5, and 7
|
Postoperative pain intensity will be assessed using an 11-point Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain), with higher scores indicating greater pain intensity.
|
2, 4, 6, 12, and 24 hours after surgery and postoperative days 3, 5, and 7
|
|
Postoperative Nausea and Vomiting Within 24 Hours
Délai: First 24 hours after surgery
|
Postoperative nausea and vomiting (PONV) will be assessed during the first 24 hours after surgery.
The occurrence of nausea and vomiting will be recorded separately, and the occurrence of either nausea or vomiting will be considered PONV.
|
First 24 hours after surgery
|
|
Cumulative Tramadol Consumption During the First 24 Postoperative Hours
Délai: First 24 hours after surgery
|
Total tramadol consumption delivered through patient-controlled analgesia (PCA) during the first 24 hours after surgery will be recorded in milligrams.
Higher values indicate greater postoperative opioid requirement.
|
First 24 hours after surgery
|
|
Requirement for Additional Analgesia During the First 24 Postoperative Hours
Délai: First 24 hours after surgery
|
The requirement for additional analgesia with intravenous paracetamol during the first 24 hours after surgery will be recorded.
The number and proportion of participants requiring at least one dose of additional analgesia will be compared between groups.
|
First 24 hours after surgery
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 25-42
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .